Related Experiment Videos
Sulfisoxazole chemoprophylaxis for frequent otitis media
Insights
Sulfisoxazole chemoprophylaxis significantly reduced recurrent otitis media episodes by 40% in young children. This safe and effective treatment also improved eustachian tube function, as shown by tympanograms.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Recurrent otitis media is a common childhood infection.
- Effective chemoprophylaxis strategies are crucial for managing frequent ear infections.
Purpose of the Study:
- To evaluate the efficacy and safety of sulfisoxazole chemoprophylaxis in preventing recurrent otitis media in children.
- To assess the impact of sulfisoxazole on eustachian tube function.
Main Methods:
- A double-blind, placebo-controlled crossover study involving 35 children aged 6 months to 5 years.
- Sulfisoxazole (75 mg/kg/d) was administered for 3 months.
- Outcomes measured included otitis media episode rates and serial tympanograms.
Main Results:
- A 40% reduction in otitis media episodes was observed with sulfisoxazole compared to placebo.
- In a subgroup receiving placebo first, sulfisoxazole reduced episodes by 64% and improved tympanograms.
- A carry-over effect suggested sustained benefits after discontinuing sulfisoxazole.
Conclusions:
- Sulfisoxazole chemoprophylaxis is a safe and effective intervention for reducing otitis media recurrence in children.
- The drug demonstrated positive effects on eustachian tube function.
- Findings support the use of sulfisoxazole for otitis media management.
Abstract:
Sulfisoxazole, 75 mg/kg/d in two divided doses for 3 months, was administered in a double-blind placebo crossover study to 35 children aged 6 months to 5 years who had frequent recurring episodes of otitis media. There was a 40% reduction in the rate of otitis media among patients receiving sulfisoxazole compared with those receiving placebo (0.25 v 0.42 episode per patient-month) which did not depend on age, sex, season, or several other factors. Using a randomized order, among patients who received placebo first, there was a 64% reduction on sulfisoxazole therapy compared with placebo (0.20 v 0.56 episode per patient-month). In this subgroup, there was significant improvement in eustachian tube function according to serial tympanograms. In the patients who received sulfisoxazole first, the rate of acute otitis remained low on placebo (0.28 v 0.30 episode per patient-month), and tympanogram patterns continued to improve after discontinuation of the active drug. These differences suggest a carry-over effect from the benefits of chemoprophylaxis. There was no significant difference in the species or sensitivity patterns of bacteria isolated from patients receiving sulisoxazole or placebo. Sulfisoxazole chemoprophylaxis appears to be safe and effective in significantly reducing episodes of otitis media and improving tympanogram patterns.